




Adaobi Lisa Olisa, Root to Rise, Nigeria

Advances in HIV post-exposure prophylaxis (PEP)

Community Perspectives

Regulatory challenges and clinical trial designs



AIDS 2026

26–31 July • Rio de Janeiro, Brazil

aids2026.org



Root to Rise



 **AIDS 2026**

Agenda

- The PEP paradox: Current Gaps in PEP Uptake and how it's linked to community-engagement
- Insights from the community: A community survey on PEP awareness, access and priorities
- Country-level Considerations
- Next Steps



Disclaimer

 AIDS 2026

The community perspectives and survey responses I'll be sharing are not scientific research findings.

They come from a short, informal survey shared through community Whatsapp groups and networks (small, self-selected groups).

Treat them not as data, but as authentic community voices meant to bring lived experience into this conversation.

26–31 July • Rio de Janeiro, Brazil

aids2026.org





 AIDS 2026

What is PEP?

Post-Exposure Prophylaxis: HIV prevention after a possible exposure

- **What it is:** a short 28-day course of antiretroviral medicines taken after a possible HIV exposure.
- **Who it's for:** anyone with a possible HIV exposure (sexual, injection-related or occupational).
- **How it works:** stops HIV from establishing infection in the body.
- **Not PrEP:** used after exposure, not ongoing prevention.

The clock matters

Within 72h

start PEP — ideally within 24h

28 days

take the full course, every day

WHO guidance: first issued 2014, updated 2024; community-based delivery & task-sharing expand who can deliver PEP and where.

The PEP journey

Possible
exposure

Start PEP
within 72h

Take daily
for 28 days

HIV acquisition
prevented

The PEP Paradox

A proven HIV prevention tool currently being underutilized



AIDS 2026

"The potential role of PEP ... continues to be neglected in prevention programmes ... underutilized due to lack of awareness, fear of stigma and health-system barriers."

— **UNAIDS 2025 Global AIDS Update**

36

countries have PEP
guidelines

6%

National guidelines include
community PEP access

No

global data on PEP use

Maisano N, et al. A global review of national guidelines of PEP for the prevention of HIV. JIAS. 2025

The lack of global, systematic data collection on PEP usage remains a challenge. While global reporting mechanisms (like the UN's GAM) track PEP policy, they currently lack the infrastructure to collect quality-assured, standardized data on PEP utilization.

Insights from the Community


A community survey on PEP awareness, access and priorities



What we heard from the Community


Community survey findings (28 respondents)

Top barriers to PEP



The 72-hour barrier: After-hours and decentralized access remain limited

Communities would use a shorter-course of PEP



Top fixes communities want: community-led demand creation, community-based delivery, pharmacy access, mobile & outreach services, and shorter course of PEP.



Country-level Considerations

What it takes to move from evidence to implementation

This is where the question shifts from "Does it work?" to "Can we deliver it sustainably, safely and equitably at scale?"

WHO guidance is the foundation: countries adapt it into national policy, tools and training.

New molecules need regulatory approval: a new product needs national regulatory approval for product access in-country.

Beyond efficacy: MoH now asks about feasibility, acceptability, pharmacovigilance & real-world use (as with CAB-LA/LEN for PBFP).

National Priorities

- Integration
- Health-system strengthening
- Sustainability (**e.g.** Nigeria integrated PrEP & PEP M&E tools)
- Operational feasibility

Bridging Community and Country

Two sides, joined by engagement across the whole continuum

What communities bring

- Lived experience & trust
- Demand & reach via peer networks
- Real-time feedback & accountability
- Knowledge of real barriers (low awareness, stigma, limited community and after hour access)



What country systems bring

- Policy & WHO-aligned guidelines
- Regulatory approval & pharmacovigilance
- Funding, supply & scale
- Integration into health systems

The bridge: engagement across the whole continuum (early, consistent, not tokenistic) builds trust, uptake and responsive programmes.

A Message to Global Leaders

"In Uganda, especially among key populations such as MSM, and people who use drugs, PEP access is limited by low awareness, stigma and criminalization.

Many fear discrimination when seeking services and delays due to limited after-hours care mean missed opportunities within the 72-hour window.

To reduce new infections, global leaders must prioritize stigma-free, decentralized, and community-led PEP delivery integrated within broader HIV prevention services.. "

— community voice from Uganda

Acknowledgement

Insights that shape the future of PEP — powered by community

To the 28 community members across 13 countries who shared their time and voices in the survey, thank you. Your insights are at the heart of this presentation.

To The Forum for Collaborative Research, for convening the series of discussions that led to this satellite, and for hosting it today, thank you.

And to the Root to Rise team (Ashley Vij, Rose Wilcher and Emory Babcock) who helped prepare these slides and strengthen this presentation, thank you.

Adaobi · Root to Rise, Nigeria · adaobi@roottorise.org